SCHEMBL19852979

SCHEMBL19852979

CCCCCCC(CC)c1ncco1

nearest known ligand 0.46

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
FAAH O00519 3/20 0.40
CES1 P23141 1/20 0.40
NR1I2 O75469 1/20 0.38
SLC2A1 P11166 1/20 0.33
GPR84 Q9NQS5 1/20 0.32
ADA P00813 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22166109 0.93 FAAH (0.42) FAAHCES1NR1I2SLC2A1GPR84
SCHEMBL20893257 0.93 FAAH (0.42) FAAHCES1NR1I2SLC2A1GPR84
SCHEMBL18934142 0.93 FAAH (0.42) FAAHCES1NR1I2SLC2A1GPR84
SCHEMBL22692970 0.93 FAAH (0.42) FAAHCES1NR1I2SLC2A1GPR84
SCHEMBL26646458 0.93 FAAH (0.36) FAAHCES1NR1I2
SCHEMBL20098073 0.92 FAAH (0.41) FAAHCES1NR1I2SLC2A1GPR84
SCHEMBL24221550 0.86 FAAH (0.32) FAAHCES1
SCHEMBL27336909 0.86 FAAH (0.38) FAAHCES1
SCHEMBL6922325 0.85 FAAH (0.40) FAAHCES1
SCHEMBL17429845 0.82 FAAH (0.32) FAAHCES1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10640510-B2 Metabotrophic glutamate receptor 5 modulators and methods use thereof SUNOVION PHARMACEUTICALS INC. (US) 2020-05-05 US disclosed
US-20190135815-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF SUNOVION PHARMACEUTICALS INC (US) 2019-05-09 US disclosed
US-10196399-B2 Metabotrophic glutamate receptor 5 modulators and methods use thereof SUNOVION PHARMACEUTICALS INC. (US) 2019-02-05 US disclosed
US-20180037585-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF SUNOVION PHARAMCEUTICALS INC. 2018-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196399-B2 Metabotrophic glutamate receptor 5 modulators and methods use thereof GRM5, GRIK5, GRM2 FAAH 378/4885CES1 960/4885NR1I2 723/4885
US-20180037585-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF GRM5, GRIK5, GRM2 FAAH 378/4885CES1 960/4885NR1I2 723/4885
US-20190135815-A1 METABOTROPHIC GLUTAMATE RECEPTOR 5 MODULATORS AND METHODS USE THEREOF GRM5, GRIK5, GRM2 FAAH 378/4885CES1 960/4885NR1I2 723/4885
US-10640510-B2 Metabotrophic glutamate receptor 5 modulators and methods use thereof GRM5, GRIK5, GRM2 FAAH 378/4885CES1 960/4885NR1I2 723/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.